In-PharmaTechnologist.com Heparin production may be moving back to Europe according to the EFCG, which cited the opening of Pharma Action's processing plant as an indication that API buyers value quality and compliance throughout the supply chain. and more »
Newswise (press release) Newswise — Hamilton, ON (Nov. 18, 2014) – McMaster University researchers have found new evidence that suggests patients with a history of adver...
MedPage Today Low-molecular weight heparin might be more cost-effective than unfractionated heparin for venous thromboembolism (VTE) prevention in critical illness, ...
The Biological SCENE A research team led by Jayachandran N. Kizhakkedathu of the University of British Columbia recently designed a reversal agent for heparin (Sci. Tr...
